New immune therapy targets EBV-Linked cancers in early trial
NCT ID NCT05707910
First seen Nov 19, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-phase study tests a new immune-based treatment for people with advanced cancers that are positive for the Epstein-Barr virus (EBV). The main goal is to check if the treatment is safe and to see how well it might shrink tumors or slow the disease. Only 6 patients who have not responded to standard therapies are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.